Alpine Immune Sciences Yönetim

Yönetim kriter kontrolleri 3/4

Alpine Immune Sciences CEO'su Mitch Gold, Jun2016 tarihinde atandı, in görev süresi 7.92 yıldır. in toplam yıllık tazminatı $ 2.92M olup, şirket hissesi ve opsiyonları dahil olmak üzere 20.5% maaş ve 79.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.019% ine doğrudan sahiptir ve bu hisseler € 791.58K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.3 yıl ve 6.1 yıldır.

Anahtar bilgiler

Mitch Gold

İcra Kurulu Başkanı

US$2.9m

Toplam tazminat

CEO maaş yüzdesi	20.5%
CEO görev süresi	7.9yrs
CEO sahipliği	0.02%
Yönetim ortalama görev süresi	4.3yrs
Yönetim Kurulu ortalama görev süresi	6.1yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Mitch Gold'un ücretlendirmesi Alpine Immune Sciences'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2024	n/a	n/a	-US$37m
Dec 31 2023	US$3m	US$599k	-US$32m
Sep 30 2023	n/a	n/a	-US$57m
Jun 30 2023	n/a	n/a	-US$59m
Mar 31 2023	n/a	n/a	-US$64m
Dec 31 2022	US$3m	US$544k	-US$58m
Sep 30 2022	n/a	n/a	-US$54m
Jun 30 2022	n/a	n/a	-US$54m
Mar 31 2022	n/a	n/a	-US$47m
Dec 31 2021	US$3m	US$523k	-US$50m
Sep 30 2021	n/a	n/a	-US$42m
Jun 30 2021	n/a	n/a	-US$34m
Mar 31 2021	n/a	n/a	-US$33m
Dec 31 2020	US$1m	US$500k	-US$28m
Sep 30 2020	n/a	n/a	-US$28m
Jun 30 2020	n/a	n/a	-US$33m
Mar 31 2020	n/a	n/a	-US$35m
Dec 31 2019	US$2m	US$485k	-US$42m
Sep 30 2019	n/a	n/a	-US$47m
Jun 30 2019	n/a	n/a	-US$48m
Mar 31 2019	n/a	n/a	-US$44m
Dec 31 2018	US$1m	US$400k	-US$36m
Sep 30 2018	n/a	n/a	-US$30m
Jun 30 2018	n/a	n/a	-US$15m
Mar 31 2018	n/a	n/a	-US$11m
Dec 31 2017	US$2m	US$300k	-US$8m

Tazminat ve Piyasa: Mitch 'ın toplam tazminatı ($USD 2.92M ) German pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 1.92M ).

Tazminat ve Kazançlar: Mitch şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Mitch Gold (55 yo)

7.9yrs

Görev süresi

US$2,921,224

Tazminat

Dr. Mitchell H. Gold, also known as Mitch, M.D., has been Executive Chairman and Chief Executive Officer at Alpine Immune Sciences Inc. since January 2015 and June 2016 respectively. Dr. Gold served as the...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Mitchell Gold	Executive Chairman & CEO	7.9yrs	US$2.92m	0.019% € 791.6k
Stanford Peng	President and Head of Research & Development	5.1yrs	US$1.75m	0.43% € 17.7m
Paul Rickey	Senior VP	7.1yrs	US$1.28m	Veri yok
Ulrich Fuhs	VP of Finance & Chief Accounting Officer	less than a year	Veri yok	0.044% € 1.8m
M. Yi	Chief Technology Officer	less than a year	Veri yok	Veri yok
Michelle Greenblatt	Director of Investor Relations & Corporate Communications	no data	Veri yok	Veri yok
Remy Durand	Chief Business Officer	4.3yrs	Veri yok	0.15% € 6.1m
Andrew Sandler	Chief Medical Officer	1.8yrs	Veri yok	Veri yok

4.3yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: 34LA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Mitchell Gold	Executive Chairman & CEO	9.3yrs	US$2.92m	0.019% € 791.6k
Robert Conway	Independent Director	6.8yrs	US$110.21k	0.073% € 3.0m
James Topper	Independent Director	7.9yrs	US$101.46k	0% € 0
Peter Thompson	Independent Director	7.9yrs	US$103.96k	0% € 0
Rafi Ahmed	Member of Scientific Advisory Board	5.5yrs	Veri yok	Veri yok
Xiangmin Cui	Independent Director	5.3yrs	US$100.21k	0% € 0
Andrew Scharenberg	Scientific Advisory Board Chairman	no data	Veri yok	Veri yok
Christopher Peetz	Independent Director	6.1yrs	US$98.96k	0.0028% € 113.6k
John Thompson	Member of Scientific Advisory Board	5.5yrs	Veri yok	Veri yok
Manish Butte	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Paul Tumeh	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
James Welsh	Member of Scientific Advisory Board	5.5yrs	Veri yok	Veri yok

6.1yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 34LA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.1 yıldır).

Alpine Immune Sciences Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insufficient new directors

Insufficient new directors

Alpine Immune Sciences, Inc. Announces Appointment of Wolfgang Dummer as Chief Medical Officer

Insufficient new directors

Insufficient new directors

Alpine Immune Sciences, Inc. Announces Board Changes

Recent updates

Alpine Immune Sciences Files Form 15

Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from NASDAQ Composite Index

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) completed the acquisition of Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders.

Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from S&P TMI Index

First quarter 2024 earnings released: US$0.28 loss per share (vs US$0.28 loss in 1Q 2023)

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into an agreement to acquire Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders for approximately $4.3 billion.

Alpine Immune Sciences, Inc Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024

Full year 2023 earnings released: US$0.64 loss per share (vs US$1.73 loss in FY 2022)

Alpine Immune Sciences, Inc. to Report Fiscal Year 2023 Results on Mar 18, 2024

Insufficient new directors

Insufficient new directors

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.42 loss in 3Q 2022)

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $149.9968 million.

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $110 million.

Alpine Immune Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Alpine Immune Sciences, Inc. Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis

New major risk - Share price stability

Alpine Immune Sciences, Inc. Announces Appointment of Wolfgang Dummer as Chief Medical Officer

Alpine Immune Sciences, Inc. Announces Initiation of Dosing in 240 mg IgA Nephropathy Cohort of Povetacicept Clinical Study (RUBY-3)

Second quarter 2023 earnings released: US$0.27 loss per share (vs US$0.60 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.28 loss per share (vs US$0.25 loss in 1Q 2022)

Full year 2022 earnings released: US$1.73 loss per share (vs US$1.98 loss in FY 2021)

Insufficient new directors

Insufficient new directors

Alpine Immune Sciences, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Alpine Immune Sciences Terminates Enrollment of Davoceticept Clinical Studies (NEON-1 and NEON-2)

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $100.0041 million.

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $100.0041 million.

Alpine Immune Sciences, Inc. Provides Clinical Updates for Its Two Wholly Owned Programs, ALPN-303 and davoceticept

Second quarter 2022 earnings released: US$0.60 loss per share (vs US$0.46 loss in 2Q 2021)

Alpine Immune Sciences, Inc. Announces Board Changes

Alpine Immune Sciences Appoints Andrew S. Sandler as Chief Medical Officer

Alpine Immune Sciences, Inc. Announces Update on ALPN-303, a Dual BAFF/APRIL Inhibitor for Systemic Lupus Erythematosus and Other Autoimmune and Inflammatory Diseases, at EULAR 2022

Alpine Immune Sciences, Inc. Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab

Alpine Immune Sciences, Inc. Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab

First quarter 2022 earnings released: US$0.25 loss per share (vs US$0.45 loss in 1Q 2021)

Alpine Immune Sciences, Inc., Annual General Meeting, Jun 16, 2022

Insufficient new directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Alpine Immune Sciences Announces Oral Presentation at the 2022 AACR Annual Meeting

Insufficient new directors

Alpine Immune Sciences, Inc. announced that it expects to receive $15 million in funding from Horizon Therapeutics Public Limited Company

Insufficient new directors

Third quarter 2021 earnings released: US$0.55 loss per share (vs US$0.28 loss in 3Q 2020)

Independent Director recently bought €84k worth of stock

Second quarter 2021 earnings released: US$0.46 loss per share (vs US$0.53 loss in 2Q 2020)

Alpine Immune Sciences Announces First Patient Dosed in Synergy, Alpn-101 Phase 2 Lupus Clinical Trial and $45 Million in Development Milestones Achieved Under Abbvie Collaboration

Alpine Immune Sciences Announces ALPN-202 Clinical Data Presented at 2021 American Society of Clinical Oncology Virtual Annual Meeting

Alpine Immune Sciences, Inc. Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting

First quarter 2021 earnings released: US$0.45 loss per share (vs US$0.30 loss in 1Q 2020)

Full year 2020 earnings released: US$1.34 loss per share (vs US$2.28 loss in FY 2019)

Alpine Immune Sciences, Inc. to Report Q4, 2020 Results on Mar 18, 2021

Alpine Immune Sciences, Inc. Announces Executive Changes

New 90-day high: €11.80

Alpine Immune Sciences Appoints Natasha A. Hernday to its Board of Directors

New 90-day high: €7.70

Independent Director recently bought €68k worth of stock

Third quarter 2020 earnings released: US$0.28 loss per share

Revenue misses expectations

Alpine Immune Sciences, Inc. to Report Q3, 2020 Results on Nov 12, 2020

First half earnings released

Alpine Immune Sciences, Inc. announced that it has received $60.000012 million in funding from a group of investors

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş